

# T John Martin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6679722/publications.pdf>

Version: 2024-02-01

130  
papers

17,156  
citations

22153

59  
h-index

19749

117  
g-index

140  
all docs

140  
docs citations

140  
times ranked

13690  
citing authors

#	ARTICLE	IF	CITATIONS
1	Multiple actions of parathyroid hormone-related protein in breast cancer bone metastasis. <i>British Journal of Pharmacology</i> , 2021, 178, 1923-1935.	5.4	36
2	Physiological and Pharmacological Roles of PTH and PTHrP in Bone Using Their Shared Receptor, PTH1R. <i>Endocrine Reviews</i> , 2021, 42, 383-406.	20.1	41
3	Bone Geometry Is Altered by Follistatin-Induced Muscle Growth in Young Adult Male Mice. <i>JBMR Plus</i> , 2021, 5, e10477.	2.7	6
4	Aspects of intercellular communication in bone and implications in therapy. <i>Bone</i> , 2021, 153, 116148.	2.9	2
5	PTH1R Actions on Bone Using the cAMP/Protein Kinase A Pathway. <i>Frontiers in Endocrinology</i> , 2021, 12, 833221.	3.5	8
6	Osteoclasts Provide Coupling Signals to Osteoblast Lineage Cells Through Multiple Mechanisms. <i>Annual Review of Physiology</i> , 2020, 82, 507-529.	13.1	154
7	The osteoblast lineage. , 2020, , 89-110.		5
8	Coupling of bone formation and resorption. , 2020, , 219-243.		4
9	Paracrine parathyroid hormone-related protein in bone: physiology and pharmacology. , 2020, , 595-621.		3
10	<i>Dmp1Cre</i> -directed knockdown of parathyroid hormone-related protein (PTHrP) in murine decidua is associated with a life-long increase in bone mass, width, and strength in male progeny. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1999-2016.	2.8	4
11	Remembering Dr John D Termine. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1647-1648.	2.8	0
12	Cortical bone maturation in mice requires SOCS3 suppression of gp130/STAT3 signalling in osteocytes. <i>ELife</i> , 2020, 9, .	6.0	21
13	Increased autophagy in EphrinB2-deficient osteocytes is associated with elevated secondary mineralization and brittle bone. <i>Nature Communications</i> , 2019, 10, 3436.	12.8	48
14	Brief exposure to full length parathyroid hormone-related protein (PTHrP) causes persistent generation of cyclic AMP through an endocytosis-dependent mechanism. <i>Biochemical Pharmacology</i> , 2019, 169, 113627.	4.4	9
15	Autocrine and Paracrine Regulation of the Murine Skeleton by Osteocyte-Derived Parathyroid Hormone-Related Protein. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 137-153.	2.8	54
16	Tolerance to sustained activation of the cAMP/Creb pathway activity in osteoblastic cells is enabled by loss of p53. <i>Cell Death and Disease</i> , 2018, 9, 844.	6.3	12
17	Integrating Endocrine and Paracrine Influences on Bone; Lessons From Parathyroid Hormone and Parathyroid Hormone-Related Protein. , 2018, , 283-299.		0
18	Parathyroid Hormone-Related Protein Negatively Regulates Tumor Cell Dormancy Genes in a PTHR1/Cyclic AMP-Independent Manner. <i>Frontiers in Endocrinology</i> , 2018, 9, 241.	3.5	25

#	ARTICLE	IF	CITATIONS
19	Abaloparatide Is an Anabolic, but Does It Spare Resorption?. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 11-16.	2.8	28
20	Coupling: The Influences of Immune and Bone Cells. , 2016, , 169-185.		8
21	Bone metastasis: the importance of the neighbourhood. <i>Nature Reviews Cancer</i> , 2016, 16, 373-386.	28.4	369
22	Parathyroid Hormone-Related Protein, Its Regulation of Cartilage and Bone Development, and Role in Treating Bone Diseases. <i>Physiological Reviews</i> , 2016, 96, 831-871.	28.8	123
23	Anabolic action of parathyroid hormone (PTH) does not compromise bone matrix mineral composition or maturation. <i>Bone</i> , 2016, 93, 146-154.	2.9	25
24	Chondrocytic EphrinB2 promotes cartilage destruction by osteoclasts in endochondral ossification. <i>Development (Cambridge)</i> , 2016, 143, 648-57.	2.5	25
25	The role of vitamin A and retinoic acid receptor signaling in post-natal maintenance of bone. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016, 155, 135-146.	2.5	53
26	Activation of PTHrP-cAMP-CREB1 signaling following p53 loss is essential for osteosarcoma initiation and maintenance. <i>ELife</i> , 2016, 5, .	6.0	38
27	Comment on: Wnt Signaling Inhibits Osteoclast Differentiation by Activating Canonical and Non-Canonical cAMP/PKA Pathways. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 2133-2134.	2.8	1
28	Coupling Signals between the Osteoclast and Osteoblast: How are Messages Transmitted between These Temporary Visitors to the Bone Surface?. <i>Frontiers in Endocrinology</i> , 2015, 6, 41.	3.5	140
29	RANKL/OPG; Critical role in bone physiology. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2015, 16, 131-139.	5.7	158
30	Wnt inhibitory factor 1 (WIF1) is a marker of osteoblastic differentiation stage and is not silenced by DNA methylation in osteosarcoma. <i>Bone</i> , 2015, 73, 223-232.	2.9	27
31	The DNA Helicase Recq14 Is Required for Normal Osteoblast Expansion and Osteosarcoma Formation. <i>PLoS Genetics</i> , 2015, 11, e1005160.	3.5	34
32	RAR $\beta$ is a negative regulator of osteoclastogenesis. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2015, 150, 46-53.	2.5	25
33	Calcitonin Physiology, Saved by a Lysophospholipid. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 212-215.	2.8	19
34	Glycoprotein130 (Gp130)/interleukin-6 (IL-6) signalling in osteoclasts promotes bone formation in periosteal and trabecular bone. <i>Bone</i> , 2015, 81, 343-351.	2.9	47
35	Isolation and gene expression of haematopoietic-cell-free preparations of highly purified murine osteocytes. <i>Bone</i> , 2015, 72, 34-42.	2.9	42
36	Bone Biology and Anabolic Therapies for Bone: Current Status and Future Prospects. <i>Journal of Bone Metabolism</i> , 2014, 21, 8.	1.3	63

#	ARTICLE	IF	CITATIONS
37	gp130 in late osteoblasts and osteocytes is required for PTH-induced osteoblast differentiation. <i>Journal of Endocrinology</i> , 2014, 223, 181-190.	2.6	26
38	PTHrP, its receptor, and protein kinase A activation in osteosarcoma. <i>Molecular and Cellular Oncology</i> , 2014, 1, e965624.	0.7	11
39	Coupling Factors: How Many Candidates Can There Be?. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 1519-1521.	2.8	12
40	Myokines (muscle-derived cytokines and chemokines) including ciliary neurotrophic factor (CNTF) inhibit osteoblast differentiation. <i>Bone</i> , 2014, 64, 47-56.	2.9	53
41	Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit. <i>BoneKey Reports</i> , 2014, 3, 481.	2.7	536
42	Oncostatin M acting via OSMR, augments the actions of IL-1 and TNF in synovial fibroblasts. <i>Cytokine</i> , 2014, 68, 101-109.	3.2	38
43	New therapeutics for osteoporosis. <i>Current Opinion in Pharmacology</i> , 2014, 16, 58-63.	3.5	26
44	The Primary Function of gp130 Signaling in Osteoblasts Is To Maintain Bone Formation and Strength, Rather Than Promote Osteoclast Formation. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 1492-1505.	2.8	90
45	EphrinB2 signaling in osteoblasts promotes bone mineralization by preventing apoptosis. <i>FASEB Journal</i> , 2014, 28, 4482-4496.	0.5	70
46	Historical Perspective and Evolutionary Origins of Parathyroid Hormone-Related Protein. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2014, 12, 104-118.	0.8	1
47	Decline in calcitonin receptor expression in osteocytes with age. <i>Journal of Endocrinology</i> , 2014, 221, 181-191.	2.6	20
48	Osteoclast-Derived Coupling Factors in Bone Remodeling. <i>Calcified Tissue International</i> , 2014, 94, 88-97.	3.1	120
49	Reflections on Development of Concepts of Intercellular Communication in Bone. , 2013, , 51-69.		0
50	Basic Principles of Bone Cell Biology. , 2013, , 5-26.		3
51	Modeling distinct osteosarcoma subtypes in vivo using Cre:lox and lineage-restricted transgenic shRNA. <i>Bone</i> , 2013, 55, 166-178.	2.9	65
52	EphrinB2/EphB4 inhibition in the osteoblast lineage modifies the anabolic response to parathyroid hormone. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 912-925.	2.8	93
53	Historically significant events in the discovery of RANK/RANKL/OPG. <i>World Journal of Orthopedics</i> , 2013, 4, 186.	1.8	54
54	Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. <i>Nature Medicine</i> , 2012, 18, 405-412.	30.7	417

#	ARTICLE	IF	CITATIONS
55	Sustained RANKL response to parathyroid hormone in oncostatin M receptor-deficient osteoblasts converts anabolic treatment to a catabolic effect in vivo. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 902-912.	2.8	49
56	Twenty-five years of PTHrP progress: From cancer hormone to multifunctional cytokine. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 1231-1239.	2.8	145
57	Interactions Among Osteoblasts, Osteoclasts, and Other Cells in Bone. , 2011, , 227-267.		3
58	Advances in the biology of bone metastasis: How the skeleton affects tumor behavior. <i>Bone</i> , 2011, 48, 6-15.	2.9	164
59	Foreword: Skeletal Complications of Cancer. <i>Bone</i> , 2011, 48, 5.	2.9	1
60	Zinc Finger Protein 467 Is a Novel Regulator of Osteoblast and Adipocyte Commitment. <i>Journal of Biological Chemistry</i> , 2011, 286, 4186-4198.	3.4	71
61	Ciliary Neurotrophic Factor Inhibits Bone Formation and Plays a Sex-Specific Role in Bone Growth and Remodeling. <i>Calcified Tissue International</i> , 2010, 86, 261-270.	3.1	62
62	Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. <i>Journal of Clinical Investigation</i> , 2010, 120, 582-592.	8.2	245
63	Matrix Rigidity Induces Osteolytic Gene Expression of Metastatic Breast Cancer Cells. <i>PLoS ONE</i> , 2010, 5, e15451.	2.5	70
64	Molecular Mechanisms in Coupling of Bone Formation to Resorption. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2009, 19, 73-88.	0.9	142
65	Advances in the molecular pharmacology and therapeutics of bone disease and international symposium on paget's disease. <i>IBMS BoneKEy</i> , 2009, 6, 439-445.	0.0	0
66	New functions for old hormones: Bone as an endocrine organ. <i>Molecular and Cellular Endocrinology</i> , 2009, 310, 1-2.	3.2	3
67	The Chemokine Cxcl1 Is a Novel Target Gene of Parathyroid Hormone (PTH)/PTH-Related Protein in Committed Osteoblasts. <i>Endocrinology</i> , 2009, 150, 2244-2253.	2.8	54
68	Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis. <i>Osteoporosis International</i> , 2008, 19, 1125-1138.	3.1	39
69	EphrinB2 Regulation by PTH and PTHrP Revealed by Molecular Profiling in Differentiating Osteoblasts. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1170-1181.	2.8	191
70	Cardiotrophin-1 Is an Osteoclast-Derived Stimulus of Bone Formation Required for Normal Bone Remodeling. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 2025-2032.	2.8	163
71	Bone remodelling: its local regulation and the emergence of bone fragility. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2008, 22, 701-722.	4.7	149
72	Model structure and control of bone remodeling: A theoretical study. <i>Bone</i> , 2008, 43, 249-263.	2.9	237

#	ARTICLE	IF	CITATIONS
73	Osteoclast Inhibitory Lectin, an Immune Cell Product That Is Required for Normal Bone Physiology in Vivo. <i>Journal of Biological Chemistry</i> , 2008, 283, 30850-30860.	3.4	28
74	Intercellular Communication during Bone Remodeling. , 2008, , 547-560.		2
75	New mechanisms and targets in the treatment of bone fragility. <i>Clinical Science</i> , 2007, 112, 77-91.	4.3	46
76	Human embryonic stem cells leap the barrier. <i>Medical Journal of Australia</i> , 2007, 187, 477-478.	1.7	0
77	Changes in Osteoblast, Chondrocyte, and Adipocyte Lineages Mediate the Bone Anabolic Actions of PTH and Small Molecule GSK-3 Inhibitor. <i>Journal of Cellular Biochemistry</i> , 2007, 102, 1504-1518.	2.6	56
78	A skeleton key to metabolism. <i>Nature Medicine</i> , 2007, 13, 1021-1023.	30.7	19
79	New agents for the treatment of osteoporosis. <i>BoneKEy Osteovision</i> , 2007, 4, 287-298.	0.6	2
80	Protein nutrition as therapy for a genetic disorder of bone?. <i>Cell Metabolism</i> , 2006, 4, 419-420.	16.2	6
81	David Valor Cohn (1926â€“2006). <i>Bone</i> , 2006, 38, 611-612.	2.9	0
82	Mechanisms Involved in Skeletal Anabolic Therapies. <i>Annals of the New York Academy of Sciences</i> , 2006, 1068, 458-470.	3.8	50
83	Orally Bioavailable GSK-3 $\beta$ Dual Inhibitor Increases Markers of Cellular Differentiation In Vitro and Bone Mass In Vivo. <i>Journal of Bone and Mineral Research</i> , 2006, 21, 910-920.	2.8	164
84	Parathyroid Hormoneâ€“Related Protein Localization in Breast Cancers Predict Improved Prognosis. <i>Cancer Research</i> , 2006, 66, 2250-2256.	0.9	124
85	Interleukin-11 Receptor Signaling Is Required for Normal Bone Remodeling. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 1093-1102.	2.8	138
86	Osteoclast-derived activity in the coupling of bone formation to resorption. <i>Trends in Molecular Medicine</i> , 2005, 11, 76-81.	6.7	550
87	Osteoblast-derived PTHrP is a physiological regulator of bone formation. <i>Journal of Clinical Investigation</i> , 2005, 115, 2322-2324.	8.2	110
88	Does bone resorption inhibition affect the anabolic response to parathyroid hormone?. <i>Trends in Endocrinology and Metabolism</i> , 2004, 15, 49-50.	7.1	40
89	Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. <i>Journal of Clinical Investigation</i> , 2004, 113, 379-389.	8.2	175
90	T-Cells Mediate an Inhibitory Effect of Interleukin-4 on Osteoclastogenesis. <i>Journal of Bone and Mineral Research</i> , 2003, 18, 984-993.	2.8	56

#	ARTICLE	IF	CITATIONS
91	Differentiation potential of a mouse bone marrow stromal cell line. <i>Journal of Cellular Biochemistry</i> , 2003, 90, 158-169.	2.6	75
92	Nuclear Transport of Parathyroid Hormone (PTH)-Related Protein Is Dependent on Microtubules. <i>Molecular Endocrinology</i> , 2002, 16, 390-401.	3.7	104
93	Manipulating the environment of cancer cells in bone: a novel therapeutic approach. <i>Journal of Clinical Investigation</i> , 2002, 110, 1399-1401.	8.2	15
94	Transforming Growth Factor $\beta_2$ Affects Osteoclast Differentiation via Direct and Indirect Actions. <i>Journal of Bone and Mineral Research</i> , 2001, 16, 1787-1794.	2.8	245
95	Catabolic Effects of Continuous Human PTH (1-38) in Vivo Is Associated with Sustained Stimulation of RANKL and Inhibition of Osteoprotegerin and Gene-Associated Bone Formation. <i>Endocrinology</i> , 2001, 142, 4047-4054.	2.8	381
96	Parathyroid Hormone-Related Protein Production by Breast Cancers, Improved Survival, and Reduced Bone Metastases. <i>Journal of the National Cancer Institute</i> , 2001, 93, 234-237.	6.3	110
97	Fetal parathyroids are not required to maintain placental calcium transport. <i>Journal of Clinical Investigation</i> , 2001, 107, 1007-1015.	8.2	110
98	Nuclear and nucleolar localization of parathyroid hormone-related protein. <i>Immunology and Cell Biology</i> , 2000, 78, 395-402.	2.3	48
99	Therapeutic Approaches to Bone Diseases. <i>Science</i> , 2000, 289, 1508-1514.	12.6	1,578
100	Osteoprotegerin Produced by Osteoblasts Is an Important Regulator in Osteoclast Development and Function*. <i>Endocrinology</i> , 2000, 141, 3478-3484.	2.8	351
101	Breast Cancer Cells Interact with Osteoblasts to Support Osteoclast Formation <sup>1</sup> . <i>Endocrinology</i> , 1999, 140, 4451-4458.	2.8	497
102	Phosphorylation at the Cyclin-dependent Kinases Site (Thr85) of Parathyroid Hormone-related Protein Negatively Regulates Its Nuclear Localization. <i>Journal of Biological Chemistry</i> , 1999, 274, 18559-18566.	3.4	86
103	Importin $\beta_2$ Recognizes Parathyroid Hormone-related Protein with High Affinity and Mediates Its Nuclear Import in the Absence of Importin $\beta_1$ . <i>Journal of Biological Chemistry</i> , 1999, 274, 7391-7398.	3.4	185
104	A novel orthotopic model of breast cancer metastasis to bone. <i>Clinical and Experimental Metastasis</i> , 1999, 17, 163-170.	3.3	367
105	Dual posttranscriptional targets of retinoic acid-induced gene expression. <i>Journal of Cellular Biochemistry</i> , 1999, 72, 411-422.	2.6	0
106	Modulation of Osteoclast Differentiation and Function by the New Members of the Tumor Necrosis Factor Receptor and Ligand Families. <i>Endocrine Reviews</i> , 1999, 20, 345-357.	20.1	2,009
107	Osteotropic Agents Regulate the Expression of Osteoclast Differentiation Factor and Osteoprotegerin in Osteoblastic Stromal Cells. <i>Endocrinology</i> , 1998, 139, 4743-4743.	2.8	404
108	A Combination of Osteoclast Differentiation Factor and Macrophage-Colony Stimulating Factor Is Sufficient for both Human and Mouse Osteoclast Formation in Vitro. <i>Endocrinology</i> , 1998, 139, 4424-4427.	2.8	384

#	ARTICLE	IF	CITATIONS
109	Expression of Rat Homeobox Gene, rHOX, in Developing and Adult Tissues in Mice and Regulation of Its mRNA Expression in Osteoblasts by Bone Morphogenetic Protein 2 and Parathyroid Hormone-Related Protein. <i>Molecular Endocrinology</i> , 1998, 12, 1721-1732.	3.7	14
110	A Combination of Osteoclast Differentiation Factor and Macrophage-Colony Stimulating Factor Is Sufficient for both Human and Mouse Osteoclast Formation in Vitro. <i>Endocrinology</i> , 1998, 139, 4424-4427.	2.8	101
111	Expression of Rat Homeobox Gene, rHOX, in Developing and Adult Tissues in Mice and Regulation of Its mRNA Expression in Osteoblasts by Bone Morphogenetic Protein 2 and Parathyroid Hormone-Related Protein. <i>Molecular Endocrinology</i> , 1998, 12, 1721-1732.	3.7	7
112	Parathyroid hormone-related protein and hypercalcemia. <i>Cancer</i> , 1997, 80, 1564-1571.	4.1	96
113	Parathyroid hormone-related protein and hypercalcemia. <i>Cancer</i> , 1997, 80, 1564-1571.	4.1	57
114	Expression of parathyroid hormone-related protein in cells of osteoblast lineage. , 1996, 166, 94-104.		100
115	Arg21 is the Preferred Kexin Cleavage Site in Parathyroid-Hormone-Related Protein. <i>FEBS Journal</i> , 1995, 229, 91-98.	0.2	22
116	Modulation of Osteoclast Differentiation. <i>Endocrine Reviews</i> , 1992, 13, 66-80.	20.1	783
117	Parathyroid hormone-related protein: a possible endocrine function in lactation. <i>Clinical Endocrinology</i> , 1992, 37, 405-410.	2.4	102
118	Plasminogen activator regulation in osteoblasts: Parathyroid hormone inhibition of type-1 plasminogen activator inhibitor and its mRNA. <i>Journal of Cellular Physiology</i> , 1992, 152, 346-355.	4.1	37
119	Transforming growth factor beta inhibits plasminogen activator (PA) activity and stimulates production of urokinase-type PA, PA inhibitor-1 mRNA, and protein in rat osteoblast-like cells. <i>Journal of Cellular Physiology</i> , 1991, 149, 34-43.	4.1	59
120	A Carboxyl-Terminal Peptide from the Parathyroid Hormone-Related Protein Inhibits Bone Resorption by Osteoclasts*. <i>Endocrinology</i> , 1991, 129, 1762-1768.	2.8	159
121	Structural requirements for the action of parathyroid hormone-related protein (PTHrP) on bone resorption by isolated osteoclasts. <i>Journal of Bone and Mineral Research</i> , 1991, 6, 85-93.	2.8	77
122	Cloning of an osteoblastic cell line involved in the formation of osteoclast-like cells. <i>Journal of Cellular Physiology</i> , 1990, 145, 587-595.	4.1	86
123	The Bone Marrow-Derived Stromal Cell Lines MC3T3-G2/PA6 and ST2 Support Osteoclast-Like Cell Differentiation in Cocultures with Mouse Spleen Cells. <i>Endocrinology</i> , 1989, 125, 1805-1813.	2.8	482
124	Parathyroid hormone-related protein relaxes rat gastric smooth muscle and shows cross-desensitization with parathyroid hormone. <i>Journal of Bone and Mineral Research</i> , 1989, 4, 433-439.	2.8	49
125	OSTEOBLASTIC CELLS ARE INVOLVED IN OSTEOCLAST FORMATION. <i>Endocrinology</i> , 1988, 123, 2600-2602.	2.8	909
126	Induction of Calcitonin Receptors by $1\alpha, 25$ - Dihydroxyvitamin D <sub>3</sub> in Osteoclast-Like Multinucleated Cells Formed from Mouse Bone Marrow Cells*. <i>Endocrinology</i> , 1988, 123, 1504-1510.	2.8	170



#	ARTICLE	IF	CITATIONS
127	HUMORAL HYPERCALCEMIA OF MALIGNANCY: INVOLVEMENT OF A NOVEL HORMONE. Australian and New Zealand Journal of Medicine, 1988, 18, 287-295.	0.5	12
128	Regulation of alkaline phosphatase expression in a neonatal rat clonal calvarial cell strain by retinoic acid. Journal of Bone and Mineral Research, 1988, 3, 53-61.	2.8	83
129	Inhibitory effects of parathyroid hormone on growth of osteogenic sarcoma cells. Calcified Tissue International, 1985, 37, 519-525.	3.1	84
130	Activity Ratio Measurements Reflect Intracellular Activation of Adenosine 3'-5'-Monophosphate-Dependent Protein Kinase in Osteoblasts*. Endocrinology, 1982, 111, 178-183.	2.8	65